PD-1 & PD-L1 Inhibitors Market by Product (Atezolizumab, Avelumab, Durvalumab), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030
The PD-1 & PD-L1 Inhibitors Market size was estimated at USD 37.11 billion in 2023 and expected to reach USD 44.61 billion in 2024, at a CAGR 20.59% to reach USD 137.65 billion by 2030.
Global PD-1 & PD-L1 Inhibitors Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the PD-1 & PD-L1 Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the PD-1 & PD-L1 Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the PD-1 & PD-L1 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Innovent Biologics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi S.A..
Market Segmentation & Coverage
This research report categorizes the PD-1 & PD-L1 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Atezolizumab
Avelumab
Durvalumab
Nivolumab
Pembrolizumab
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the PD-1 & PD-L1 Inhibitors Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the PD-1 & PD-L1 Inhibitors Market?
3. What are the technology trends and regulatory frameworks in the PD-1 & PD-L1 Inhibitors Market?
4. What is the market share of the leading vendors in the PD-1 & PD-L1 Inhibitors Market?
5. Which modes and strategic moves are suitable for entering the PD-1 & PD-L1 Inhibitors Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. PD-1 & PD-L1 Inhibitors Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
- 5.1.1.2. Growing presence of patient assistance programs
- 5.1.1.3. Rising public awareness and increasing healthcare expenses
- 5.1.2. Restraints
- 5.1.2.1. High cost of cancer immunotherapy
- 5.1.3. Opportunities
- 5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
- 5.1.3.2. Technological innovations and advancements in cancer screening procedures
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory scenario
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. PD-1 & PD-L1 Inhibitors Market, by Product
- 6.1. Introduction
- 6.2. Atezolizumab
- 6.3. Avelumab
- 6.4. Durvalumab
- 6.5. Nivolumab
- 6.6. Pembrolizumab
- 7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacies
- 7.3. Online Pharmacies
- 7.4. Retail Pharmacies
- 8. Americas PD-1 & PD-L1 Inhibitors Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Akeso Inc.
- 12.1.2. Alphamab Oncology
- 12.1.3. Amgen Inc.
- 12.1.4. AstraZeneca PLC
- 12.1.5. BeiGene Ltd.
- 12.1.6. Bristol Myers Squibb Company
- 12.1.7. Eli Lilly and Company
- 12.1.8. F. Hoffmann La Roche Ltd.
- 12.1.9. Gilead Sciences Inc.
- 12.1.10. GlaxoSmithKline PLC
- 12.1.11. Innovent Biologics Inc.
- 12.1.12. Merck KGaA
- 12.1.13. Novartis AG
- 12.1.14. Pfizer Inc.
- 12.1.15. Regeneron Pharmaceuticals Inc.
- 12.1.16. Sanofi S.A.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
- FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2023 VS 2030
- FIGURE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
- FIGURE 7. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook